Robuta

https://www.medsciencescapital.com/news/prosensa-begins-nda-submission-to-the-fda-for-exon-skipping-drug-drisapersen-to-treat-duchenne-muscular-dystrophy/
exon skippingprosensabeginsndasubmission
https://www.jci.org/articles/view/117052/scanned-page/1041
jciidentificationnovelexonicmutation
https://www.mdpi.com/2673-5261/6/1/5
Introduction: MET Exon 14 skipping alterations are drivers of non-small cell lung carcinoma (NSCLC) with responses to tyrosine kinase inhibitors....
challengesampliconbaseddnangs